NRG Administrative Core Abstract The NRG Oncology (NRG) Administrative Core provides the leadership and infrastructure necessary to support the largest portfolio of clinical trials among the adult groups in the NCI National Clinical Trail Network (NCTN), a membership encompassing over 220 main member sites ? including nearly every Lead Academic Participating Site (LAPS) and a robust contribution to the overall management and success of the NCTN. NRG utilizes a highly successful multiple-PI model to provide remarkably capable leadership and scientific oversight, dynamic committee leadership and mentoring, knowledgeable and experienced administrative and operational leadership, and appropriate associated support. NRG, a group formed only four years ago, has leveraged the strengths of its legacy groups to form an integrated, modern clinical trials organization addressing specific populations within the NCTN. It is notable that NRG remained highly productive in all realms even while navigating the merger of the three legacy groups, a testament to the remarkable leadership of NRG and the thoughtful organizational structure put into place. In addition to supporting its own goals, NRG is a highly collaborative member of the NCTN. NRG co-led a number of trials with other groups, championed sixteen studies from other groups, participated in numerous NCI-appointed steering committees, workgroups, and task forces, and led the development of new remote monitoring standards. NRG has the leadership and infrastructure in place to continue to support the clinical trial and membership goals as well as continue to serve as engaged stakeholders in the overall management and success of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180868-06
Application #
9627154
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-16
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Geyer Jr, Charles E; Tang, Gong; Mamounas, Eleftherios P et al. (2018) 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 4:37
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2018) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol 41:396-401
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Bell, Erica H; Zhang, Peixin; Fisher, Barbara J et al. (2018) Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol 4:1405-1409
Lukka, Himanshu R; Pugh, Stephanie L; Bruner, Deborah W et al. (2018) Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys 102:287-295
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Bandos, Hanna; Melnikow, Joy; Rivera, Donna R et al. (2018) Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 110:
Coen, John J; Zhang, Peixin; Saylor, Philip J et al. (2018) Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol :JCO1800537
Crook, Juanita M; Zhang, Peixin; Pisansky, Thomas M et al. (2018) A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526). Int J Radiat Oncol Biol Phys :

Showing the most recent 10 out of 357 publications